(Q36496168)

14 August 2017

1 reference

title

Safety of rituximab maintenance therapy in follicular lymphomas (English)

1 reference

14 August 2017

1 reference

Philippe Solal-Céligny

series ordinal

1

1 reference

14 August 2017

1 March 2006

1 reference

14 August 2017

1 reference

14 August 2017

30 Suppl 1

1 reference

14 August 2017

S16-21

1 reference

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980004-4

7 January 2021

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980004-4

7 January 2021

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980004-4

7 January 2021

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980004-4

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980004-4

7 January 2021

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980004-4

7 January 2021

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980004-4

7 January 2021

Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980004-4

7 January 2021

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980004-4

7 January 2021

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980004-4

7 January 2021

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980004-4

7 January 2021

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980004-4

7 January 2021

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980004-4

7 January 2021

Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980004-4

7 January 2021

First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980004-4

7 January 2021

Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980004-4

7 January 2021

Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980004-4

7 January 2021

B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980004-4

7 January 2021

Neutropenia in patients treated with rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980004-4

7 January 2021

Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980004-4

7 January 2021

Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980004-4

7 January 2021

Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group fo

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980004-4

7 January 2021

10.1016/S0145-2126(06)80004-4

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16750674